Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients. in Current research in pharmacology and drug discovery / Curr Res Pharmacol Drug Discov. 2024 Feb 16;6:100178. doi: 10.1016/j.crphar.2024.100178. eCollection

2024
ASL Vercelli
AOU Città della Salute di Torino

Tipo pubblicazione

Journal Article

Autori/Collaboratori (55)Vedi tutti...

Alarico A
Azienda ULSS 6 Euganea, Rheumatology Outpatient Clinic, Padova, Italy.
Enrico F
Azienda Ospedaliero-Universitaria di Parma, Department of Medicine, Internal Medicine and Rheumatology Unit, Parma, Italy.
Francesca O
IRCCS Ospedale Sacro Cuore Don Calabria, Rheumatology Unit, Negrar, Italy.

et alii...

Abstract

OBJECTIVES: The persistence in therapy of rheumatoid arthritis drugs and particularly bDMARD is a limiting factor for their long-term use. The randomized controlled trials (RCTs) may not reflect real-world contexts due to strict inclusion and exclusion criteria. Baricitinib, which targets both JAK1 and JAK2, has been used in Italy for several years. The aim of this multi-center study is to assess the real world persistence on therapy of baricitinib in RA patients and to identify predictive factors of baricitinib's survival rate. METHODS: This is a retrospective, multicentric, Italian, longitudinal study. All patients were enrolled according to the following criteria: a) age ? 18 years old; b) diagnosed with RA according 2010 ACR/EULAR classification criteria; c) treated with baricitinib. In order to describe baricitinib clinical efficacy, the survival rate was evaluated by The Kaplan-Meier curve. Then, predictive factors of drug retention rate were assessed by performing the Cox analysis, identifying which risk factors influenced treatment persistence. RESULTS: Overall, we included 478 patients treated with baricitinib. Among them, 380 (79.5%) were females. Baricitinib's survival rate was 94.6% at 6 months, 87.9% at 12 months, 81.7% at 24 months and 53.4% at 48 months. The Cox analysis regression showed that a higher bDMARDs/tsDMARD line of therapy seems to be a negative prognostic factor for the drug retention rate (HR 1.26 CI 95% 1.07-1.49, p = 0.006. CONCLUSION: Real-life study confirms baricitinib effectiveness up to 4 years, but previous treatment with bDMARDs was a negative prognostic factor for its survival rate.

Accesso banca dati bibliografica

PMID : 38419949

DOI : 10.1016/j.crphar.2024.100178

Keywords

Survival rate; Rheumatoid arthritis; Prognostic factor; Real world; Line of treatment; JAK inhibitors; Comorbidity; Baricitinib; bDMARD; tsDMARD;